Sugi Predict

Sugi Predict / Compounds / SCHEMBL4638846

SCHEMBL4638846

SCHEMBL4638846

Cc1ccc(-c2ccccc2-c2nnn(C(c3ccccc3)(c3ccccc3)c3ccccc3)n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 2/20 0.46
▸ AGTR1 P30556 2/20 0.44
▸ NPC1 O15118 7/20 0.41
▸ RAB9A P51151 7/20 0.41
▸ MAPT P10636 5/20 0.41
▸ POLB P06746 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.37
▸ NFKB1 P19838 2/20 0.36
▸ NFKB2 Q00653 2/20 0.36
▸ RELA Q04206 2/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ SENP6 Q9GZR1 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30743612 0.90 ABCG2 (0.55) ABCG2AGTR1NPC1RAB9AMAPT
SCHEMBL9137872 0.88 SMN1; SMN2 (0.46) NPC1RAB9AMAPTPOLBSMN1; SMN2
SCHEMBL2161550 0.88 ABCG2 (0.41) ABCG2AGTR1NPC1RAB9AMAPT
SCHEMBL7772778 0.88 ABCG2 (0.44) ABCG2AGTR1NPC1RAB9AMAPT
SCHEMBL15391225 0.86 AGTR1 (0.47) ABCG2AGTR1NPC1RAB9AMAPT
SCHEMBL9430611 0.84 ABCG2 (0.45) ABCG2NPC1RAB9AMAPTPOLB
SCHEMBL4638349 0.84 AGTR1 (0.47) ABCG2AGTR1RAB9APOLBSMN1; SMN2
SCHEMBL9315829 0.83 AGTR1 (0.42) ABCG2AGTR1POLBSMN1; SMN2TP53
SCHEMBL4638150 0.83 AGTR1 (0.45) ABCG2AGTR1NPC1RAB9AMAPT
SCHEMBL9429727 0.83 AGTR1 (0.43) ABCG2AGTR1POLBSMN1; SMN2AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114733575-A Palladium-loaded molecular sieve catalyst and preparation method and application thereof 浙江天宇药业股份有限公司 2022-07-12 — — CN disclosed
CN-114733526-A Nickel-loaded porous carbon material catalyst and preparation method and application thereof 浙江天宇药业股份有限公司 2022-07-12 — — CN disclosed
US-8563586-B2 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation ELDRUG S.A. (GR) 2013-10-22 — — US disclosed
US-8563586-B2 1,(3,)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation ELDRUG S.A. (GR) 2013-10-22 — — US disclosed
US-7923566-B2 Alternative process for the preparation of losartan SUVEN LIFE SCIENCES LIMITED (IN) 2011-04-12 — — US disclosed
US-20100190996-A1 Process for the Preparation of Losartan SUVEN LIFE SCIENCES, LTD (IN) 2010-07-29 — — US disclosed
US-20100166837-A1 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION ELDRUG S.A. (GR) 2010-07-01 — — US disclosed
US-20100166837-A1 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION ELDRUG S.A. (GR) 2010-07-01 — — US disclosed
EP-1384717-B1 2-(2'-triphenylmethyl-2'H-tetrazol-5'-yl)phenylboronic acid intermediates for the synthesis of A II receptor antagonists DU PONT (US) 2008-05-14 — — EP disclosed
US-20070072923-A1 Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde SUMITOMO CHEMICAL COMPANY, LIMITED 2007-03-29 — — US disclosed
EP-0470795-B1 Process for the manufacture of nitriles ZENECA LTD (GB) 1995-01-25 — — EP disclosed
US-5371233-A 2-(tetrazol-5-yl)-1,1'-biphenyl derivatives, their preparation and their use as synthetic intermediates SYNTHELABO (FR) 1994-12-06 — — US disclosed
US-5310928-A Process for preparing biphenyltetrazole compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-05-10 — — US disclosed
US-5206374-A Process for preparing tetrazolylphenylboronic acid intermediates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-04-27 — — US disclosed
EP-0470795-A1 Process for the manufacture of nitriles ZENECA LIMITED (GB) 1992-02-12 — — EP disclosed
EP-0470794-A1 Process for the preparation of nitriles ZENECA LIMITED (GB) 1992-02-12 — — EP disclosed
EP-0467207-A2 Purinderivate F. HOFFMANN-LA ROCHE AG (CH) 1992-01-22 — — EP disclosed
EP-0455423-A2 Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl) benzenes MERCK & CO. INC. (US) 1991-11-06 — — EP disclosed
WO-1991013063-A1 NEW BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-09-05 — — WO disclosed
US-5039814-A Chemical intermediates for angiotensin antagonist MERCK & CO., INC. (US) 1991-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166837-A1 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION AGTR1, AGTR2, AGT ABCG2 119/4885AGTR1 1/4885NPC1 639/4885
US-20070072923-A1 Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde TH, CYP4B1, ABL1 ABCG2 118/4885AGTR1 816/4885NPC1 4000/4885
US-20100190996-A1 Process for the Preparation of Losartan AGTR1, AGT, AGTR2 ABCG2 3451/4885AGTR1 1/4885NPC1 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.